Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06462781 · ClinicalTrials.gov registry record · Phase 1
Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1
A Phase 1 study, sponsored by The Cooper Health System.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT06462781 is a Phase 1 study that has completed, run by The Cooper Health System. The registered enrollment target is 10 participants.
The verdict
NCT06462781, a Phase 1 study, has completed, sponsored by The Cooper Health System.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test whether injecting lidocaine and steroids into two blood vessels of the brain can help treat chronic headaches (migraines). The main questions this study aims to answer: is this treatment safe for chronic migraine patients? Participants will: * Be treated once with lidocaine and steroid infused into the middle meningeal arteries (two blood vessels in the brain). * Attend appointments scheduled 1 week, 6 weeks, and 12 weeks after the treatment for a checkup. * Keep a log of their symptoms.
Interventions
- DRUG Lidocaine hydrochloride
- DRUG Methylprednisolone sodium succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2025-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06462781
The ClinicalTrials.gov registry entry for NCT06462781 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cooper Health System, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lidocaine hydrochloride is the first listed.
NCT06462781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06462781 about?
NCT06462781 is a clinical study titled "Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1". The goal of this clinical trial is to test whether injecting lidocaine and steroids into two blood vessels of the brain can help treat chronic headaches (migraines). The main questions this study aims to answer: is this treatment safe for chronic migraine patients? Participants will: * Be treated...
What is the current status of trial NCT06462781?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-03-15. Estimated completion is 2025-06-01.
What interventions are being tested in trial NCT06462781?
The interventions under investigation include: Lidocaine hydrochloride (DRUG), Methylprednisolone sodium succinate (DRUG).
Who is sponsoring clinical trial NCT06462781?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.